Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 99 of the 101 references it cites were found in a registry or an index; 34 of the 87 sources its claims cite were checked for support.

Clinical use of lentiviral vectors

Open access

Abstract

Viral vectors provide an efficient means for modification of eukaryotic cells, and their use is now commonplace in academic laboratories and industry for both research and clinical gene therapy applications. Lentiviral vectors, derived from the human immunodeficiency virus, have been extensively investigated and optimized over the past two decades. Third-generation, self-inactivating lentiviral vectors have recently been used in multiple clinical trials to introduce genes into hematopoietic stem cells to correct primary immunodeficiencies and hemoglobinopathies. These vectors have also been used to introduce genes into mature T cells to generate immunity to cancer through the delivery of chimeric antigen receptors (CARs) or cloned T-cell receptors. CAR T-cell therapies engineered using lentiviral vectors have demonstrated noteworthy clinical success in patients with B-cell malignancies leading to regulatory approval of the first genetically engineered cellular therapy using lentiviral vectors. In this review, we discuss several aspects of lentiviral vectors that will be of interest to clinicians, including an overview of lentiviral vector development, the current uses of viral vectors as therapy for primary immunodeficiencies and cancers, large-scale manufacturing of lentiviral vectors, and long-term follow-up of patients treated with gene therapy products.

Overview

CoChat Summary

## TL;DR

This review explains why third-generation, self-inactivating lentiviral vectors have become important tools for clinical gene therapy, especially for modifying hematopoietic stem cells and T cells. It highlights early clinical success in CAR T-cell therapy and summarizes safety, manufacturing, and regulatory issues that still need long-term follow-up.

## Key findings

  • Third-generation, self-inactivating lentiviral vectors have been used in multiple clinical trials to introduce genes into hematopoietic stem cells for primary immunodeficiencies and hemoglobinopathies, and into mature T cells for cancer immunotherapy via CARs or cloned T-cell receptors.
  • In a trial using a lentiviral vector to transfer a TCR specific for a peptide shared by NY-ESO-1 and LAGE-1 in multiple myeloma, clinical responses were observed in 16 of 20 patients, with minimal safety concerns.
  • CD19-targeted CAR T-cell therapies engineered with lentiviral or retroviral vectors showed strong efficacy in B-cell acute lymphoblastic leukemia, with durable complete response rates in >60% of patients with relapsed or refractory disease, and approximately 40 to 70% complete response rates in non-Hodgkin lymphoma.
  • For gene transfer into β-thalassemia, one patient with βE/β0-thalassemia achieved transfusion independence; however, this was associated with a dominant myeloid clone containing a lentiviral vector insertion in the HMGA2 locus.
  • The review states that no adverse events attributable to the lentiviral vector were reported in the cited trials of T cells and HSCs, and that no cases of leukemogenesis have been reported to date in gene therapy trials involving lentiviral-vector-modified HSCs or non-dividing T cells.

## Methods

  • Narrative review of the development, clinical use, manufacturing, regulatory oversight, and future directions of lentiviral vectors.
  • Synthesizes published clinical and preclinical studies across HSC gene therapy, T-cell engineering, cancer vaccines, gene editing, and in vivo delivery; no new primary dataset is presented.
  • Summarizes evidence from clinical trials, phase 1/2 studies, and model systems to discuss efficacy and safety.

## Limitations

  • The paper explicitly notes that the safety of lentiviral vectors in ex vivo gene transfer into HSCs remains a somewhat open question and that longer follow-up will be necessary to fully establish safety in this setting.
  • It states that continued follow-up of patients receiving lentiviral-vector-based gene therapies is still needed to understand long-term safety and efficacy.
  • Evident from the text: this is a review article, so its conclusions depend on the quality and completeness of the cited studies rather than on a single controlled primary experiment.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41375-018-0106-0

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Steps of reverse transcription. This figure illustrates the steps involved in the conversion of the single-stranded RNA (ssRNA) genome of HIV into double-stranded DNA (dsDNA). RNA is shown in red and DNA as yellow [1]. The transfer RNA (tRNA) primer (blue ellipse) is base paired to the primer-binding site (PBS) [2]. Reverse transcription is initiated using the reverse transcriptase (RT; purple ellipse) enzyme, and minus-strand DNA synthesis starts from the tRNA primer, copying the U5 and R sequences at the 5′ end of the genome. At this stage, an RNA/DNA duplex is created, and ribonuclease (RNase) H activity of the RT enzyme degrades the viral RNA that has been copied (dotted red line) [3, 4]. The minus-strand DNA has been transferred, using the R sequence found at both ends of the viral RNA, to the 3′ end of the viral RNA, and minus-strand DNA synthesis continues. The HIV-1 genome has two RNase H-resistant polypurine tracts (PPTs) [5]. The two PPTs serve as primers for plus-strand DNA synthesis. One plus-strand is initiated at U3, and one is initiated at the central PPT (cPPT) [6]. Both the plus- and minus-strand DNAs are then elongated, finally resulting in a complete copy of viral RNA with additional sequences at the 5′ and 3′ ends such that viral DNA has an identical copy of U3RU5 at both ends. The plus-strand that was initiated at U3 displaces a segment of the plus-strand that was initiated from the cPPT, creating a small flap called the central flap (cFLAP). LTR long terminal repeat
Fig. 1 Steps of reverse transcription. This figure illustrates the steps involved in the conversion of the single-stranded RNA (ssRNA) genome of HIV into double-stranded DNA (dsDNA). RNA is shown in red and DNA as yellow [1]. The transfer RNA (tRNA) primer (blue ellipse) is base paired to the primer-binding site (PBS) [2]. Reverse transcription is initiated using the reverse transcriptase (RT; purple ellipse) enzyme, and minus-strand DNA synthesis starts from the tRNA primer, copying the U5 and R sequences at the 5′ end of the genome. At this stage, an RNA/DNA duplex is created, and ribonuclease (RNase) H activity of the RT enzyme degrades the viral RNA that has been copied (dotted red line) [3, 4]. The minus-strand DNA has been transferred, using the R sequence found at both ends of the viral RNA, to the 3′ end of the viral RNA, and minus-strand DNA synthesis continues. The HIV-1 genome has two RNase H-resistant polypurine tracts (PPTs) [5]. The two PPTs serve as primers for plus-strand DNA synthesis. One plus-strand is initiated at U3, and one is initiated at the central PPT (cPPT) [6]. Both the plus- and minus-strand DNAs are then elongated, finally resulting in a complete copy of viral RNA with additional sequences at the 5′ and 3′ ends such that viral DNA has an identical copy of U3RU5 at both ends. The plus-strand that was initiated at U3 displaces a segment of the plus-strand that was initiated from the cPPT, creating a small flap called the central flap (cFLAP). LTR long terminal repeatCC BY · PubMed Central
Fig. 2 Third-generation lentiviral vector. Third-generation lentiviral vectors are composed of two separate packaging plasmids, one encoding gag and pol and another encoding rev. An additional plasmid encodes the envelope protein, derived from the VSV-G. The plasmid encoding the gene of interest contains lentiviral LTR sequences that have been altered to be self-inactivating (SIN) to prevent recombination. LTR long terminal repeat, VSV vesicular stomatitis virus
Fig. 2 Third-generation lentiviral vector. Third-generation lentiviral vectors are composed of two separate packaging plasmids, one encoding gag and pol and another encoding rev. An additional plasmid encodes the envelope protein, derived from the VSV-G. The plasmid encoding the gene of interest contains lentiviral LTR sequences that have been altered to be self-inactivating (SIN) to prevent recombination. LTR long terminal repeat, VSV vesicular stomatitis virusCC BY · PubMed Central
Fig. 3 Overview of large-scale vector manufacturing. Manufacture of a lentiviral vector begins with the culture of a packaging cell line in a facility that uses Good Manufacturing Practices. The cells are transfected with the plasmids that make up the third-generation lentiviral vector, and the vector-producing cells are expanded in culture. The vector is purified from the cells and culture debris and filtered to ensure sterility, and individual aliquots are cryopreserved
Fig. 3 Overview of large-scale vector manufacturing. Manufacture of a lentiviral vector begins with the culture of a packaging cell line in a facility that uses Good Manufacturing Practices. The cells are transfected with the plasmids that make up the third-generation lentiviral vector, and the vector-producing cells are expanded in culture. The vector is purified from the cells and culture debris and filtered to ensure sterility, and individual aliquots are cryopreservedCC BY · PubMed Central
Fig. 4 Key clinical uses of lentiviral vectors. a Correction of primary immunodeficiency. Using a viral vector to deliver the common gamma chain (γc) restores immune function in patients with SCID-X1. b Delivery of a tumor-specific T-cell receptor (TCR). A lentiviral vector can be used to introduce the MART-1 TCR, which recognizes a melanoma antigen, into a patient’s T cells ex vivo. The modified T cells, which now recognize melanoma cells, are administered to the patient as a cancer therapy. c Chimeric antigen receptor (CAR) T-cell therapy. A CAR engineered from three distinct domains (antigen recognition, co-stimulatory signaling, and T-cell signaling) can be introduced into T cells using a lentiviral vector. The cells expressing the modified receptor recognize the antigen of interest and harness the potent cytotoxic activity of T cells to attack tumor cells. Currently, most CAR T-cell therapies in clinical trials target the CD19 antigen, a protein expressed on B cells and B-cell malignancies. SCID severe combined immunodeficiency
Fig. 4 Key clinical uses of lentiviral vectors. a Correction of primary immunodeficiency. Using a viral vector to deliver the common gamma chain (γc) restores immune function in patients with SCID-X1. b Delivery of a tumor-specific T-cell receptor (TCR). A lentiviral vector can be used to introduce the MART-1 TCR, which recognizes a melanoma antigen, into a patient’s T cells ex vivo. The modified T cells, which now recognize melanoma cells, are administered to the patient as a cancer therapy. c Chimeric antigen receptor (CAR) T-cell therapy. A CAR engineered from three distinct domains (antigen recognition, co-stimulatory signaling, and T-cell signaling) can be introduced into T cells using a lentiviral vector. The cells expressing the modified receptor recognize the antigen of interest and harness the potent cytotoxic activity of T cells to attack tumor cells. Currently, most CAR T-cell therapies in clinical trials target the CD19 antigen, a protein expressed on B cells and B-cell malignancies. SCID severe combined immunodeficiencyCC BY · PubMed Central

Verification

Claims the paper makes

30 Valid · 5 Not valid · 37 Not checked · 43 Own results and interpretations

63 more claims · 14 with their cited sources checked

Create a free account to see all 115 claims and to verify the 15 references still open.

See all claims — free account
  • It may state two separate claims as one. 34
  • Probably not a substantial claim. 19

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 101 references

Research works printed but not linked: 1

  1. Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341:1233158. · DOI · Paper page

Cited by

See all 930

Metadata

Authors
Milone, M. C., & O’Doherty, U.
Affiliations
University of Pennsylvania (US)
Corresponding author
Milone, Michael C.
Venue
Leukemia
Published
2018-03-22
Volume
32
Issue
7
Pages
1529-1541
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2791408070
Cited by
930
References
101
Citations by year
2026: 125 · 2025: 123 · 2024: 156 · 2023: 108 · 2022: 125 · 2021: 126 · 2020: 109 · 2019: 43 · 2018: 14
FWCI
10.09
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Leukemia (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Novartis Pharmaceuticals Corporation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
lentiviral vectors, gene therapy, CAR T-cell therapy, chimeric antigen receptor, primary immunodeficiency, hemoglobinopathies, hematopoietic stem cells, T cell engineering, B-cell malignancies, long-term follow-up, self-inactivating vectors, viral vector development
MeSH terms
Clinical Studies as Topic, Animals, Genetic Engineering, Genetic Vectors, Humans, Transduction, Genetic, Genetic Therapy, Lentivirus, Gene Transfer Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical use of lentiviral vectors. https://app.cochat.ai/papers/10.1038/s41375-018-0106-0
The paper
Milone, M. C., & O’Doherty, U. (2018). Clinical use of lentiviral vectors. Leukemia. https://doi.org/10.1038/s41375-018-0106-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.